Having trouble viewing this email? View in your browser.

This email contains promotional information from Tillotts Pharma.
Prescribing information can be found via a link at the bottom of this email.

Thank you for joining us at ECCMID 2021 Congress!

We are pleased to have been part of the world’s premier Clinical Microbiology & Infectious Diseases event, which brought together experts from relevant fields to present the latest findings and developments and share their expertise.

We hoped you had time to join us on our stand where we were showcasing our newest addition to the Tillotts Pharma GI portfolio, DIFICLIRTM.

A narrow-spectrum macrocyclic anti-bacterial agent, DIFICLIR is available as film-coated tablets. It is indicated for the treatment of CDI, also known as C. difficile-associated diarrhoea (CDAD), in adults and paediatric patients with a body weight of at least 12.5 kg.1

What makes DIFICLIR an effective treatment, is that it is a first-in-class oral macrocyclic antibacterial, with a unique mechanism of action targeting C. difficile RNA polymerase:1,2

This enables DIFICLIR to directly target C. difficile bacteria, preserving the natural microbiome that protects against recurrence.3,4 This contrasts with broad-spectrum antibiotics such as vancomycin, which 'knock out' the natural microbiome. As vancomycin cannot directly kill bacterial spores, some dormant C. difficile spores can remain after treatment. These can germinate before the natural microbiome has fully recovered, leading to recurrence of C. difficile infection (CDI). When you prescribe DIFICLIR, you have assurance of knowing it's significantly more effective than vancomycin for reducing recurrence of CDI.5,6

If you would like to find out more about DIFICLIR and how it can help your patients, please contact us to find your local representative.

Contact Us

GI: gastrointestinal
References
1. DIFICLIR (fidaxomicin), Summary of Product Characteristics.
2. Zhanel et al. Can J Infect Dis Med Microbiol 2015; 26: 305-312.
3. Vickers RJ, et al. Int J Antimicrob Agents 2016; 48: 137-143.
4. Chilton et al. Antimicrob Chemother 2014; 69:451-462
5. Louie TJ, et al. N Engl J Med 2011;364:422–31.
6. Cornely OA, et al. Lancet Infect Dis 2012;12:281–9

Click here for prescribing information

Adverse events should be reported.

You have received this email as a contact of ESCMID or one of its affiliated societies.
You can unsubscribe here.